Evaluating Primary Treatment for People with Advanced Glaucoma
Assessed by RV005 · Statistician
Assessed on 11 Nov 2025
OverallReviewer's overall integrity assessment, derived from all research questions No concerns
DOI 10.1016/j.ophtha.2024.01.007 (opens in new tab)
Resource ripekg:research-integrity-assessment/RIPEA07C7CD7A66B0506A
5 Research Questions · 2 Evidence Items
Q1.1 — Does the study have an associated retraction?
Rationale: Agree
Q1.2 — Does the study have an associated expression of concern or other relevant post-publication notice?
Rationale: Agree
Q1.3 — Do other studies by the research team highlight causes for concern?
Rationale: Agree
Q2.2 — Are there concerns relating to the timing or absence of study registration?
Rationale: Agree
Supporting Evidence (2)
Clinical Trial RegistrationSource: Clinical trial registry (e.g. ClinicalTrials.gov, ISRCTN)
Registration ID: ISRCTN56878850
Registry: ISRCTN
Registry Link: https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN56878850 (opens in new tab)
Registration Date: 14/01/2014
Prospective:Whether the trial was registered before participant recruitment began Yes
Assessment Rationale:How INSPECT-AI determined the prospective registration status by comparing dates Registration date is on or before LLM recruitment start date.
Study Design EvidenceDates and timelines extracted by INSPECT-AI from the publication text
Recruitment Start: 03-06-2014
Recruitment Start Rationale:INSPECT-AI's reasoning for how it identified the recruitment start date Participants were recruited from June 3, 2014.
Recruitment End: 31-05-2017
Recruitment End Rationale:INSPECT-AI's reasoning for how it identified the recruitment end date Participants were recruited until May 31, 2017.
Study End: N/A
Study End Rationale:INSPECT-AI's reasoning for how it identified the study end date No explicit study end date found; only the follow-up duration (5 years) is mentioned.
Overall — What is the overall integrity assessment of the study?
Rationale: Agree